Percutaneous tricuspid valve repair: A safer alternative to traditional approaches?

Abstract

Key Points The use of the PASCAL transcatheter valve repair system is a safe and feasible approach for treating patients with severe, symptomatic tricuspid regurgitation and is associated with improved quality‐of‐life outcomes at 30 days. The TriCLASP study adds to the growing body of evidence supporting the use of transcatheter tricuspid valve interventions for treating severe tricuspid regurgitation in high‐risk surgical patients. In the highly anticipated CLASP II TR pivotal trial (NCT04097145), patients will be randomized to receive treatment with the PASCAL system and optimal medical therapy or optimal medical therapy alone.